(4-碘-2,5-二甲基苯)胺 | 117832-13-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: (4-碘-2,5-二甲基苯)胺
• 英文名称: 2,5-dimethyl-4-iodoaniline
• 英文别名: 4-iodo-2,5-dimethylaniline；4-iodo-2,5-dimethyl-aniline；4-Jod-2,5-dimethyl-anilin；4-Iodo-2,5-dimethyl-phenylamine；2,5-dimethyl-4-iodo-aniline
• CAS: 117832-13-0
• 化学式: C₈H₁₀IN
• mdl: MFCD04138433
• 分子量: 247.079
• InChiKey: JIJNBUOAWDGTHA-UHFFFAOYSA-N

物化性质

• 熔点：
  69 °C(Solv: methanol (67-56-1); water (7732-18-5))
• 沸点：
  290.7±28.0 °C(Predicted)
• 密度：
  1.688±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  10
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  26
• 氢给体数：
  1
• 氢受体数：
  1

安全信息

• 海关编码：
  2921430090

反应信息

• 作为反应物：
  描述：

  (4-碘-2,5-二甲基苯)胺 生成 1,4-二碘-2,5-二甲苯
  参考文献：
  名称：

  EFFECTS OF A SAW PALMETTO HERBAL BLEND IN MEN WITH SYMPTOMATIC BENIGN PROSTATIC HYPERPLASIA

  摘要：

  Purpose: We tested the effects of a saw palmetto herbal blend in men with symptomatic benign prostatic hyperplasia (BPH) via a randomized, placebo controlled trial.Materials and Methods: We randomized 44 men 45 to 80 years old with symptomatic BPH into a trial of a saw palmetto herbal blend versus placebo. End points included routine clinical measures (symptom score, uroflowmetry and post-void residual urine volume), blood chemistry studies (prostate specific antigen, sex hormones and multiphasic analysis), prostate volumetrics by magnetic resonance imaging, and prostate biopsy for zonal tissue morphometry and semiquantitative histology studies.Results: Saw palmetto herbal blend and placebo groups had improved clinical parameters with a slight advantage in the saw palmetto group (not statistically significant). Neither prostate specific antigen nor prostate volume changed from baseline. Prostate epithelial contraction was noted, especially in the transition zone, where percent epithelium decreased from 17.8% at baseline to 10.7% after 6 months of saw palmetto herbal blend (p <0.01). Histological studies showed that the percent of atrophic glands increased from 25.2% to 40.9% after treatment with saw palmetto herbal blend (p <0.01). The mechanism of action appeared to be nonhormonal but it was not identified by tissue studies of apoptosis, cellular proliferation, angiogenesis, growth factors or androgen receptor expression. We noted no adverse effects of saw palmetto herbal blend. When the study was no longer blinded, 41 men elected to continue therapy in an open label extension.Conclusions: Saw palmetto herbal blend appears to be a safe, highly desirable option for men with moderately symptomatic BPH. The secondary outcome measures of clinical effect in our study were only slightly better for saw palmetto herbal blend than placebo (not statistically significant). However, saw palmetto herbal blend therapy was associated with epithelial contraction, especially in the transition zone (p <0.01), indicating a possible mechanism of action underlying the clinical significance detected in other studies.

  DOI：

  10.1016/s0022-5347(05)67641-0
• 作为产物：
  描述：

  1-碘-2,5-二甲基-4-硝基苯 在 盐酸 、 溶剂黄146 、 tin(ll) chloride 作用下， 生成 (4-碘-2,5-二甲基苯)胺
  参考文献：
  名称：

  Mascarelli; Longo, Gazzetta Chimica Italiana, 1941, vol. 71, p. 297,299

  摘要：

  DOI：

文献信息

• Iodination of anilines and phenols with 18-crown-6 supported ICl2−
  作者：Hannah W. Mbatia、Olbelina A. Ulloa、Daniel P. Kennedy、Christopher D. Incarvito、Shawn C. Burdette

  DOI：10.1039/c0ob00926a

  日期：——

  A highly crystalline iodinating reagent, [K·18-C-6]ICl2}n, was synthesized in high yield (93%). The trihalide is supported by an 18-crown-6 macrocycle and forms a coordination polymer in the solid state. This reagent iodinates anilines and phenols efficiently under mild conditions. Controlled mono-iodination with anilines was easily achieved while poly-iodination was observed with phenols.

  高结晶性的碘化试剂[K·18-C-6]ICl2}n以高产率（93%）合成。该三卤化物由18-冠-6大环支撑，并在固态下形成配位聚合物。该试剂在温和条件下高效碘化苯胺和酚。通过苯胺实现了可控的单碘化，而酚则观察到多碘化作用。
• Substituted Pyrrolidine-2-Carboxamides
  申请人：Ding Qingjie

  公开号：US20100075948A1

  公开（公告）日：2010-03-25

  There are provided compounds of the formula wherein X, Y, R 1 , R 2 , R 3 , R 3 , R 4 , R 5 , R 6 and R 7 are as described herein and enantiomers and pharmaceutically acceptable salts and esters thereof. The compounds are useful as anticancer agents.

  提供了以下式的化合物 其中X、Y、R1、R2、R3、R3、R4、R5、R6和R7如本文所述，以及其对映体和药用可接受的盐和酯。这些化合物可用作抗癌药物。
• Regioselective iodination of aryl amines using 1,4-dibenzyl-1,4-diazoniabicyclo [2.2.2] octane dichloroiodate in solution and under solvent-free conditions
  作者：M. Alikarami、S. Nazarzadeh、M. Soleiman-Beigi

  DOI：10.4314/bcse.v29i1.15

  日期：——

  1,4-Dibenzyl-1,4-diazoniabicyclo[2.2.2]octane dichloroiodate is an efficient and regioselective reagent for iodination of aryl amines. A wide variety of aryl amines in reaction with this reagent afforded regioselectively iodinated products. The iodination reaction can be carried out in solution or under solvent-free condition at room temperature.

  1,4-二苄基-1,4-二氮鎓二环[2.2.2]辛烷二氯碘酸盐是一种高效的区域选择性碘化试剂，适用于芳香胺的碘化反应。多种芳香胺与该试剂反应，均能区域选择性地生成碘化产物。该碘化反应可以在室温下于溶液中或无溶剂条件下进行。
• Halogenation Using Quaternary Ammonium Polyhalides. VII. Iodination of Aromatic Amines by Use of Benzyltrimethylammonium Dichloroiodate(1—)
  作者：Shoji Kajigaeshi、Takaaki Kakinami、Hiromichi Yamasaki、Shizuo Fujisaki、Tsuyoshi Okamoto

  DOI：10.1246/bcsj.61.600

  日期：1988.2

  The reaction of aromatic amines with benzyltrimethylammonium dichloroiodate(1—) in dichloromethane–methanol in the presence of calcium carbonate powder for several hours at room temperature gave se...

  芳香胺与二氯碘酸苄基铵（1-）在二氯甲烷-甲醇中，在碳酸钙粉末的存在下，在室温下反应几个小时，得到了...
• [EN] DIAMIDE COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND ß2 ADRENERGIC RECEPTOR AGONIST ACTIVITY<br/>[FR] COMPOSES DIAMIDES AYANT UN ANTAGONISTE DU RECEPTEUR MUSCARINIQUE ET UNE ACTIVITE AGONISTE DES RECEPTEURS ADRENERGIQUES BETA2
  申请人：THERAVANCE INC

  公开号：WO2010123766A1

  公开（公告）日：2010-10-28

  This invention relates to a compound of formula I; or a pharmaceutically acceptable salt thereof. Such compounds possess both muscarinic receptor antagonist and β2 adrenergic receptor agonist activities. The invention also relates to pharmaceutical compositions comprising such compounds, processes and intermediates for preparing such compounds, and methods of using such compounds as bronchodilating agents to treat pulmonary disorders.

  这项发明涉及公式I的化合物；或其药学上可接受的盐。这些化合物具有毛细血管收缩受体拮抗剂和β2肾上腺素受体激动剂活性。该发明还涉及包含这些化合物的药物组合物、制备这些化合物的过程和中间体，以及将这些化合物用作支气管扩张剂治疗肺部疾病的方法。